期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

宫颈腺癌及其血管内介入治疗 被引量：7

Intravascular interventional therapy for uterine cervical adenocarcinoma
下载PDF
导出
摘要 与鳞癌比较,年轻患者中宫颈腺癌发病呈上升趋势,预后亦较差。传统的放疗和静脉途径化疗在肿瘤的治疗中均难以取得好的疗效。宫颈腺癌的分子生物学行为有别于鳞癌。其原发灶与局部浸润灶均较长时间局限于盆腔内,这为宫颈腺癌的血管内介入治疗提供了可靠的临床病理学基础。本文就宫颈腺癌的临床病理特点、分子生物学研究及血管内介入治疗作一综述。 Adenocarcinoma of the uterine cervix shows an upward trend in younger patients with poorer prognosis in comparing with squamous carcinoma. The traditional radiotherapy and intravenous route chemotherapy are all difficult in treating uterine cervical adenocarcinoma due to different biomolecular characterization with that of the squamous cell carcinoma. Because of long term growth for primary lesion and infiltration with limitation inside the pelvis, provides a reliable clinieo-pathologle basis for intra-vascular interventional treatment. This article presents a comprehensive statement of elinieo-pathologie, biomolecular investigation and intravaseular intervention for uterine cervical carcinoma.
作者 吕益忠 陈亚梅
机构地区 江苏大学附属镇江市第四人民医院
出处 《介入放射学杂志》 CSCD 2008年第10期750-753,共4页 Journal of Interventional Radiology
关键词 宫颈腺癌 分子生物学 介入 Adenoeareinoma Uterine cervix Biomoleeular Interventional treatment
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Chao A, Wang TH, Lee YS, et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression [J]. Int J Cancer, 2006, 119:91 -98.
  • 2Wong YH, Sahota DS, Cheung TH. et al. Expression pattern associated with radiotherapy sensitivity in cervical cancer [J]. Cancer, 2006, 3:189 - 195.
  • 3Fregnani JH, Latorre MR, Novik PR, et al. Assessment of pelvic lymph node micrometastatic disease in stages IB and IIA of carcinoma of the uterine cervix[J]. Int Jec Gynol Cancer, 2006, 16:1188 - 1194.
  • 4Baalbergen A,Ewing-Graham PC, Hop WC, et al. Prognosticfactors in adenocarcinoma of the uterine cervix [J]. Gynecol Oncol, 2004, 92:262 - 267.
  • 5Noriyuki M, Sumi T, Zhi X, et al. Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women[J]. Int J Oncol, 2007, 31:531 -536.
  • 6Lona M. Tomicie 1, Dotlic S, etal. Denocarcinoma of uterine cervix-prngnostic significance of clinicopathologic parameters[J]. Croat Med J, 2005, 46:397 - 403.
  • 7Chargui R, Damak T, Khornsi B, et al. prognostic factors and clinicopathologic characteristics of invasive adencarcinoma of the uterine cervix [J]. Am J Obstet. Gynecol, 2006, 194:43 - 48.
  • 8Nagai N, Hirata E, Kusuda T, et al. Villoglandular papillary adenoeareinoma of the uterine cervix responding to neoadjuvanlchemotherapy with docetaxel and cisplatin: report[J]. Int J Gvnecol Cancer, 2005, 15: 1187- 1190.
  • 9程晓东,谢幸,吕卫国.局部晚期宫颈癌新辅助化疗临床应用的进展[J].中华医学杂志,2005,85(30):2154-2156. 被引量：31
  • 10Leung TW, Xue WC, Cheung AN, et al. Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix [J], Gynecol Oncol, 2004, 92: 866- 872.

二级参考文献18

  • 1Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol,2001,20:179-188.
  • 2Timotheadou E, Gore ME. Neoadjuvant chemotherapy for locally advanced cervical cance. Eur J Cancer, 2003,39 : 2419 -2421.
  • 3Hwang YY, Moon H, Cho SH, et al. Ten-year survival of patients with locally advanced, stage Ⅰ b - Ⅱb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol,2001,82:88-93.
  • 4Aoki Y, Tomita M, Sato T, et al. Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamous cell carcinoma of the cervix. Gynecol Oncol,2001,83 :263-267.
  • 5Tabata T, Takeshima N, Nishida H, et al. A randomized study of primary bleomycin, vincristine, mitomycin and cisplatin ( BOMP )chemotherapy followed by radiotherapy versus radiotherapy alone in stage mb and lVa squamous cellcarcinoma of the cervix. Anticancer Res.2003.23:2885-2890.
  • 6Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer,2002,38:270-278.
  • 7Sardi JE,Giaroli A,Sananes C ,et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ⅰb squamous carcinoma of the cervix: the final results. Gynecol Oncol,1997,67:61-69.
  • 8Duenas-Gonzalez A, Rivera L, Mota A. The advantages of concurrent chemoradiation after neoadjuvant chemotherapy for locally advanced cervical carcinoma. Arch Med Res ,2002,33:201-202.
  • 9Duenas-Gonzalez A, Lopez-graniel C, Gonzalez-Enciso A, et al. Aphase Ⅱ study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol,2003,14 : 1278-1284.
  • 10Benedet J1, Hacker NF, Ngan HYS, et al. Staging classifications and clinical practice guidelines of gynaecologic cancer, http://www. figo. org/content/PDF/staging-booklet, pdf.

共引文献30

同被引文献63

引证文献7

二级引证文献36

介入放射学杂志
2008年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部